- Home
- APRE vs IMRN Comparison
APRE vs IMRN Comparison
Compare APRE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- IMRN
- Stock Information
- Founded
- APRE 2006
- IMRN 1994
- Country
- APRE United States
- IMRN Australia
- Employees
- APRE N/A
- IMRN N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- IMRN Health Care
- Exchange
- APRE Nasdaq
- IMRN Nasdaq
- Market Cap
- APRE 9.4M
- IMRN 9.2M
- IPO Year
- APRE 2019
- IMRN N/A
- Fundamental
- Price
- APRE $1.69
- IMRN $1.81
- Analyst Decision
- APRE Strong Buy
- IMRN Strong Buy
- Analyst Count
- APRE 1
- IMRN 1
- Target Price
- APRE $20.00
- IMRN $5.00
- AVG Volume (30 Days)
- APRE 60.0K
- IMRN 82.1K
- Earning Date
- APRE 08-12-2025
- IMRN 09-08-2025
- Dividend Yield
- APRE N/A
- IMRN N/A
- EPS Growth
- APRE N/A
- IMRN N/A
- EPS
- APRE N/A
- IMRN N/A
- Revenue
- APRE $841,012.00
- IMRN $4,048,286.00
- Revenue This Year
- APRE N/A
- IMRN N/A
- Revenue Next Year
- APRE N/A
- IMRN N/A
- P/E Ratio
- APRE N/A
- IMRN N/A
- Revenue Growth
- APRE N/A
- IMRN 82.90
- 52 Week Low
- APRE $1.41
- IMRN $1.50
- 52 Week High
- APRE $5.01
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- APRE 46.79
- IMRN 58.51
- Support Level
- APRE $1.66
- IMRN $1.62
- Resistance Level
- APRE $1.79
- IMRN $1.84
- Average True Range (ATR)
- APRE 0.14
- IMRN 0.09
- MACD
- APRE -0.01
- IMRN 0.02
- Stochastic Oscillator
- APRE 38.89
- IMRN 89.55
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.